This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
25.—(1) A product which is, or which contains, a beta-agonist or hormonal substance complies with the requirements of this regulation if—
(a)a marketing authorisation has been issued in relation to it;
(b)in the case of a product which is, or which contains, a beta-agonist, it has a withdrawal period of less than 28 days after the end of treatment; and
(c)in the case of a product which is, or which contains, a hormonal substance, it is not a product which falls within paragraph (2) below.
(2) A product falls within this paragraph if it—
(a)acts as a deposit;
(b)has a withdrawal period of more than 15 days after the end of treatment; or
(c)was authorised before 1st January 1995, has no known conditions of use and for which no reagents or equipment exists for use in the analytical techniques for detecting the presence of residues in excess of the prescribed limits.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
